{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,15]],"date-time":"2025-11-15T03:30:37Z","timestamp":1763177437464,"version":"3.45.0"},"reference-count":52,"publisher":"Japanese Society of Internal Medicine","issue":"22","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2025,11,15]]},"DOI":"10.2169\/internalmedicine.5006-24","type":"journal-article","created":{"date-parts":[[2025,5,28]],"date-time":"2025-05-28T18:07:06Z","timestamp":1748455626000},"page":"3203-3213","source":"Crossref","is-referenced-by-count":0,"title":["Clinical Utility of an Increased Pretreatment Immature Platelet Fraction in the Early Diagnosis of TAFRO Syndrome, Especially in Patients with Late-onset Thrombocytopenia: A Case Series and Literature Review"],"prefix":"10.2169","volume":"64","author":[{"given":"Tomoyuki","family":"Saga","sequence":"first","affiliation":[{"name":"Department of Hematology, Kin-ikyo Chuo Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michiyo","family":"Kanagawa","sequence":"additional","affiliation":[{"name":"Department of Hematology, Kin-ikyo Chuo Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomoya","family":"Harada","sequence":"additional","affiliation":[{"name":"Department of Hematology, Kin-ikyo Chuo Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshimichi","family":"Ishihara","sequence":"additional","affiliation":[{"name":"Department of Hematology, Kin-ikyo Chuo Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"962","reference":[{"key":"1","unstructured":"1. Takai K, Nikkuni K, Shibuya H, Hashidate H. Thrombocytopenia with mild bone marrow fibrosis accompanied by fever, pleural effusion, ascites and hepatosplenomegaly. Rinsho Ketsueki (Jpn J Clin Hematol) 51: 320-325, 2010 (in Japanese, Abstract in English)."},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Masaki Y, Kawabata H, Takai K, et al. Proposed diagnostic criteria, disease severity classification and treatment strategy for TAFRO syndrome, 2015 version. Int J Hematol 103: 686-692, 2016.","DOI":"10.1007\/s12185-016-1979-1"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Masaki Y, Kawabata H, Takai K, et al.; Japanese TAFRO Syndrome Research Team. 2019 Updated diagnostic criteria and disease severity classification for TAFRO syndrome. Int J Hematol 111: 155-158, 2020.","DOI":"10.1007\/s12185-019-02780-1"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Fujimoto S, Sakai T, Kawabata H, et al. Is TAFRO syndrome a subtype of idiopathic multicentric Castleman disease? Am J Hematol 94: 975-983, 2019.","DOI":"10.1002\/ajh.25554"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Castleman B, Towne VW. CASE records of Massachusetts General Hospital weekly clinicopathological exercises: case 40011. N Eng J Med 250: 26-30, 1954.","DOI":"10.1056\/NEJM195401072500107"},{"key":"6","doi-asserted-by":"publisher","unstructured":"6. Fajgenbaum DC, van Rhee F, Nabel CS. HHV-8-negative, idiopathic multicentric Castleman disease: novel insights into biology, pathogenesis, and therapy. Blood 123: 2924-2933, 2014.","DOI":"10.1182\/blood-2013-12-545087"},{"key":"7","doi-asserted-by":"publisher","unstructured":"7. Fajgenbaum DC, Uldrick TS, Bagg A, et al. International, evidence-based consensus diagnostic criteria for HHV-8-negative\/idiopathic multicentric Castleman disease. Blood 129: 1646-1657, 2017.","DOI":"10.1182\/blood-2016-10-746933"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Nishimura Y, Fajgenbaum DC, Pierson SK, et al. Validated international definition of the TAFRO clinical subtype of idiopathic multicentric Castleman disease. Am J Hematol 96: 1241-1252, 2021.","DOI":"10.1002\/ajh.26292"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Iwaki N, Fajgenbaum DC, Nabel CS, et al. Clinicopathologic analysis of TAFRO syndrome demonstrates a distinct subtype of HHV-8-negative multicentric Castleman disease. Am J Hematol 91: 220-226, 2016.","DOI":"10.1002\/ajh.24242"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Briggs C, Kunka S, Hart D, Oguni S, Machin SJ. Assessment of an immature platelet fraction (IPF) in peripheral thrombocytopenia. Br J Haematol 126: 93-99, 2004.","DOI":"10.1111\/j.1365-2141.2004.04987.x"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Abe Y, Wada H, Tomatsu H, et al. A simple technique to determine thrombopoiesis level using immature platelet fraction (IPF). Thromb Res 118: 463-469, 2006.","DOI":"10.1016\/j.thromres.2005.09.007"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Joergensena MK, Bathuma L. Reference intervals for mean platelet volume and immature platelet fraction determined on a sysmex XE5000 hematology analyzer. Scand J Clin Lab Invest 76: 172-176, 2016.","DOI":"10.3109\/00365513.2015.1124448"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Ko YJ, Hur M, Kim H, Choi SG, Moon HW, Yun YM. Reference interval for immature platelet fraction on Sysmex XN hematology analyzer: a comparison study with Sysmex XE-2100. Clin Chem Lab Med 53: 1091-1097, 2015.","DOI":"10.1515\/cclm-2014-0839"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Kashiwagi H, Kuwana M, Murata M, et al.; Committee for Reference Guide for diagnosis of adult ITP Research Team for Coagulopathy and Other Intractable Diseases supported by the Ministry of Health, Labor and Welfare Science Research Grant Project: Research on Health Care Policy for Intractable Diseases. Reference guide for the diagnosis of adult primary immune thrombocytopenia, 2023 edition. Int J Hematol 119: 1-13, 2023.","DOI":"10.1007\/s12185-023-03672-1"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Ferreira FLB, Colella MP, Medina SS, et al. Evaluation of the immature platelet fraction contribute to the differential diagnosis of hereditary, immune and other acquired thrombocytopenias. Sci Rep 7: 3355, 2017.","DOI":"10.1038\/s41598-017-03668-y"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Sugimori N, Kondo Y, Shibayama M, et al. Aberrant increase in the immature platelet fraction in patients with myelodysplastic syndrome: a marker of karyotypic abnormalities associated with poor prognosis. Eur J Haematol 82: 54-60, 2009.","DOI":"10.1111\/j.1600-0609.2008.01156.x"},{"key":"17","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1186\/s12885-022-10059-8","volume":"22","author":"J Zhu","year":"2022","unstructured":"17. Zhu J, Lemaire P, Mathis S, et al. Machine learning-based improvement of MDS-CBC score brings platelets into the limelight to optimize smear review in the hematology laboratory. BMC Cancer 22: 972, 2022.","journal-title":"BMC Cancer","ISSN":"https:\/\/id.crossref.org\/issn\/1471-2407","issn-type":"print"},{"key":"18","unstructured":"18. Saga T, Ishihara T, Kanagawa M, et al. Clinical significance of chronologic immature platelet fraction analysis in TAFRO syndrome. Rinsho Ketsueki (Jpn J Clin Hematol) 59: 991-996, 2018 (in Japanese, Abstract in English)."},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Kanda Y. Investigation of the freely available easy-to-use software &apos;EZR&apos; for medical statistics. Bone Marrow Transplant 48: 452-458, 2013.","DOI":"10.1038\/bmt.2012.244"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Fujiwara S, Mochinaga H, Nakata H, et al. Successful treatment of TAFRO syndrome, a variant type of multicentric Castleman disease with thrombotic microangiopathy, with anti-IL-6 receptor antibody and steroids. Int J Hematol 103: 718-723, 2016.","DOI":"10.1007\/s12185-016-1978-2"},{"key":"21","unstructured":"21. Nagai Y, Ando S, Honda N, et al. TAFRO syndrome showing cholangitis on liver biopsy. Rinsho Ketsueki (Jpn J Clin Hematol) 57: 2490-2495, 2016 (in Japanese, Abstract in English)."},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Noda-Narita S, Sumida K, Sekine A, et al. TAFRO syndrome with refractory thrombocytopenia responding to tocilizumab and romiplostim: a case report. CEN Case Rep 7: 162-168, 2018.","DOI":"10.1007\/s13730-018-0319-0"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Hibi A, Mizuguchi K, Yoneyama A, et al. Severe refractory TAFRO syndrome requiring continuous renal replacement therapy complicated with <i>Trichosporon asahii<\/i> infection in the lungs and myocardial infarction: an autopsy case report and literature review. Ren Replace Ther 4: 16, 2018.","DOI":"10.1186\/s41100-018-0157-8"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. Morita K, Fujiwara S, Ikeda T, et al. TAFRO syndrome with an anterior mediastinal mass and lethal autoantibody-mediated thrombocytopenia: an autopsy case report. Acta Haematol 141: 158-163, 2019.","DOI":"10.1159\/000492743"},{"key":"25","unstructured":"25. Matsuhisa T, Takahashi N, Nakaguro M, et al. Fatal case of TAFRO syndrome associated with over-immunosuppression: a case report and review of the literature. Nagoya J Med Sci 81: 519-528, 2019."},{"key":"26","doi-asserted-by":"crossref","unstructured":"26. Sakaki A, Hosoi H, Kosako H, et al. Successful combination treatment with rituximab, steroid pulse therapy, plasma exchange and romiplostim for very severe TAFRO syndrome. Leuk Lymphoma 63: 2499-2502, 2022.","DOI":"10.1080\/10428194.2022.2074992"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27. Kanda M, Kitamura K, Saito A, Hayashi K, Suzuki T. A case of thrombocytopenia, anasarca (edema, pleural effusion, and ascites), fever, reticulin fibrosis\/renal dysfunction, and organomegaly (TAFRO) syndrome initially not presenting with thrombocytopenia: a role of immature platelet fraction. Cureus 16: e58772, 2024.","DOI":"10.7759\/cureus.58772"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28. Kawashima M, Usui T, Okada H, et al. TAFRO syndrome: 2 cases and review of the literature. Mod Rheumatol 27: 1093-1097, 2017.","DOI":"10.3109\/14397595.2015.1059982"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29. Behnia F, Elojeimy S, Matesan M, Fajgenbaum DC. Potential value of FDG PET-CT in diagnosis and follow-up of TAFRO syndrome. Ann Hematol  96: 497-500, 2017.","DOI":"10.1007\/s00277-016-2875-8"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30. Nagayama Y, Yamano M, Yagame M, et al. TAFRO syndrome as a cause of glomerular microangiopathy: a case report and literature review. BMC Nephrol 20: 375, 2019.","DOI":"10.1186\/s12882-019-1574-9"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31. Fujita K, Hatta K. Tufted-angioma-like lesion associated with vascular endothelial growth factor and interleukin-6 in TAFRO syndrome: is it a common histological feature of multicentric Castleman disease\/POEMS syndrome? J Cutan Pathol 46: 280-284, 2019.","DOI":"10.1111\/cup.13415"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32. Marchetti M, Feyles E, Zinzani P. Frontline siltuximab and rituximab in TAFRO syndrome: a case report. Eur J Haematol 105: 505-507, 2020.","DOI":"10.1111\/ejh.13473"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33. Shimada K, Sasaki T, Okabe M, et al. TAFRO syndrome with kidney involvement: a case series of patients with kidney biopsies. Kidney Med 3: 286-293, 2021.","DOI":"10.1016\/j.xkme.2020.10.011"},{"key":"34","doi-asserted-by":"crossref","unstructured":"34. Hayashi M, Wada J, Fujita M, et al. TAFRO syndrome complicated by porto-sinusoidal vascular liver disease with portal hypertension: a case report. Clin J Gastroenterol 14: 1711-1717, 2021.","DOI":"10.1007\/s12328-021-01515-2"},{"key":"35","doi-asserted-by":"crossref","unstructured":"35. Sato H, Okada F, Baba H, et al. A case of TAFRO syndrome with pulmonary abnormalities. J Thorac Imaging 36: W115-W117, 2021.","DOI":"10.1097\/RTI.0000000000000616"},{"key":"36","doi-asserted-by":"crossref","unstructured":"36. Akagi Y, Kato T, Yamashita Y, et al. Intracranial hemorrhage in a patient with TAFRO syndrome treated with cyclosporine A and rituximab. Medicina (Kaunas) 57: 971, 2021.","DOI":"10.3390\/medicina57090971"},{"key":"37","doi-asserted-by":"crossref","unstructured":"37. Minomo S, Fujiwara Y, Sakashita S, Takamura A, Nagata K. A severe case of thrombocytopenia, anasarca, fever, renal insufficiency or reticulin fibrosis, and organomegaly syndrome with myocardial and skeletal muscle calcification despite hypocalcemia: a case report. J Med Case Rep 15: 3, 2021.","DOI":"10.1186\/s13256-020-02588-2"},{"key":"38","doi-asserted-by":"crossref","unstructured":"38. Lust H, Gong S, Remiker A, Rossoff J. Idiopathic multicentric Castleman disease with TAFRO clinical subtype responsive to IL-6\/JAK inhibition: a pediatric case series. Pediatr. Blood Cancer e29261, 2021.","DOI":"10.1002\/pbc.29261"},{"key":"39","doi-asserted-by":"crossref","unstructured":"39. Montazeripouragha A, Campbell CM, Russell J, et al. Thrombocytopenia, anasarca, and severe inflammation. Am J Hematol 97: 1374-1380, 2022.","DOI":"10.1002\/ajh.26651"},{"key":"40","doi-asserted-by":"crossref","unstructured":"40. Jung H, Jeon HK, Kim HJ, Kim SH. Immature platelet fraction: establishment of a reference interval and diagnostic measure for thrombocytopenia. Korean J Lab Med 30: 451-459, 2010.","DOI":"10.3343\/kjlm.2010.30.5.451"},{"key":"41","doi-asserted-by":"crossref","unstructured":"41. Ko YJ, Kim H, Hur M, et al. Establishment of reference interval for immature platelet fraction. Int J Lab Hematol 35: 528-533, 2013.","DOI":"10.1111\/ijlh.12049"},{"key":"42","doi-asserted-by":"crossref","unstructured":"42. Ali U, Knight G, Gibbs R, Tsitsikas DA. Reference intervals for absolute and percentage immature platelet fraction using the Sysmex XN-10 automated haematology analyser in a UK population. Scand J Clin Lab Invest 77: 658-664, 2017.","DOI":"10.1080\/00365513.2017.1394488"},{"key":"43","doi-asserted-by":"crossref","unstructured":"43. Igawa T, Sato Y. TAFRO syndrome. Hematol Oncol Clin North Am 32: 107-118, 2018.","DOI":"10.1016\/j.hoc.2017.09.009"},{"key":"44","doi-asserted-by":"crossref","unstructured":"44. Mizuno H, Sawa N, Watanabe S, et al. The clinical and histopathological feature of renal manifestation of TAFRO syndrome. Kidney Int Rep 5: 1172-1179, 2020.","DOI":"10.1016\/j.ekir.2020.05.004"},{"key":"45","doi-asserted-by":"crossref","unstructured":"45. Ubara Y, Sawa N. Renal involvement in TAFRO syndrome: a review. Clin Exp Nephrol 29: 21-28, 2025.","DOI":"10.1007\/s10157-024-02573-9"},{"key":"46","doi-asserted-by":"crossref","unstructured":"46. Benlachgar N, Doghmi K, Masrar A, Mahtat EM, Harmouche H, Mezalek ZT. Immature platelets: a review of the available evidence. Thromb Res 195: 43-50, 2020.","DOI":"10.1016\/j.thromres.2020.06.048"},{"key":"47","doi-asserted-by":"crossref","unstructured":"47. Miyazaki K, Koike Y, Kunishima S, et al. Immature platelet fraction measurement is influenced by platelet size and is a useful parameter for discrimination of macrothrombocytopenia. Hematology 20: 587-592, 2015.","DOI":"10.1179\/1607845415Y.0000000021"},{"key":"48","doi-asserted-by":"crossref","unstructured":"48. Saigo K, Takenokuchi M, Imai J, et al. Usefulness of immature platelet fraction for the clinical evaluation of myelodysplastic syndromes. Lab Hematol 15: 13-16, 2009.","DOI":"10.1532\/LH96.09003"},{"key":"49","doi-asserted-by":"crossref","unstructured":"49. Senchenkova EY, Komoto S, Russell J, et al. Interleukin-6 mediates the platelet abnormalities and thrombogenesis associated with experimental colitis. Am J Pathol 183: 173-181, 2013.","DOI":"10.1016\/j.ajpath.2013.03.014"},{"key":"50","doi-asserted-by":"crossref","unstructured":"50. Kraakman MJ, Lee MK, Al-Sharea A, et al. Neutrophil-derived S100 calcium-binding proteins A8\/A9 promote reticulated thrombocytosis and atherogenesis in diabetes. J Clin Invest 127: 2133-2147, 2017.","DOI":"10.1172\/JCI92450"},{"key":"51","doi-asserted-by":"crossref","unstructured":"51. Yamaguchi Y, Maeda Y, Shibahara T, et al. Recovery from prolonged thrombocytopenia in patients with TAFRO syndrome: case series and literature review. Mod Rheumatol Case Rep 4: 302-309, 2020.","DOI":"10.1080\/24725625.2020.1717747"},{"key":"52","unstructured":"52. Masaki Y. TAFRO syndrome. Ketsuekinaika (Hematology) 77: 79-85, 2018 (in Japanese)."}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/64\/22\/64_5006-24\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,15]],"date-time":"2025-11-15T03:27:30Z","timestamp":1763177250000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/64\/22\/64_5006-24\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,15]]},"references-count":52,"journal-issue":{"issue":"22","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.5006-24","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"type":"print","value":"0918-2918"},{"type":"electronic","value":"1349-7235"}],"subject":[],"published":{"date-parts":[[2025,11,15]]},"article-number":"5006-24"}}